Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Nabilone
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Sponsor : Ault Global Holdings
Deal Size : $3.0 million
Deal Type : Acquisition
Ault Global Holdings Announces Agreement to Acquire up to 40% of Adtech Pharma, Inc.
Details : NB-110 comprises of a synthetic cannabinoid Nabilone in the absence of any preservative and its formulation mimics a human tear to drive efficacious delivery through the cornea to the retina and optical nerves in the back of eye.
Brand Name : NB-110
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 28, 2021
Lead Product(s) : Nabilone
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Sponsor : Ault Global Holdings
Deal Size : $3.0 million
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?